Oncomine Myeloid DNA Only Assay GX V2 (DNA Only)

What is Oncomine Myeloid DNA‑Only Assay GX v2 (DNA) test?

The Oncomine Myeloid DNA only Assay GX v2 is a targeted NGS test that detects single nucleotide variants (SNVs), insertions/deletions (indels), and copy‑number variations (CNVs) across key DNA genes implicated in myeloid cancers. It is optimized for genomic profiling from blood or bone marrow samples, making it highly suitable for haematology diagnostics.

With Agilus panel, Clinicians can access the reports in 3 working days (earlier 15-20 days) enabling faster clinical decisions & patient treatment outcomes

Why consider Oncomine Myeloid DNA‑Only Assay GX v2 (DNA) test?

Oncomine Myeloid panel should be considered because -

• Faster TAT – Clinicians can access the reports in 3 working days (earlier 15-20 days) enabling faster clinical decisions & patient treatment outcomes
• Precise mutation detection: Identifies clinically actionable DNA mutations across a curated set of myeloid malignancy–associated genes.
• Helps guide therapy decisions for effective treatment planning.
• Detects high‑risk mutations that influence disease stratification.
• A single assay replacing multiple single‑gene tests, reducing time and conserving sample.
• Provides molecular information that may support minimal residual disease considerations and trial enrollment for novel therapies.

Who should get this Oncomine Myeloid DNA‑Only Assay GX v2 (DNA) test?

• Patients with suspected or confirmed myeloid neoplasms (AML, MDS, MPN, CMML, etc.) who require genetic characterization for diagnosis and classification.
• Individuals being evaluated for targeted therapy options (e.g., FLT3 or IDH inhibitors).
• Patients undergoing risk stratification before hematopoietic stem cell transplant or intensive therapy.
• Cases where broad, simultaneous genetic testing is preferred over stepwise single‑mutation assays for faster and more comprehensive decision support.

More Information about Oncomine Myeloid DNA only Assay (DNA) test

The Oncomine Myeloid DNA only Assay (DNA) test is a next-generation sequencing (NGS) panel specifically designed for the genomic characterization of myeloid malignancies such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and related neoplasms. This assay focuses on clinically relevant mutations in genes associated with hematologic cancers, analyzing DNA alterations that drive disease biology, prognosis, and therapeutic response.

With Agilus Oncomine Myeloid DNA panel, clinicians can access the reports in 3 working days (earlier 15-20 days) enabling faster clinical decisions & patient treatment outcomes

Other Names: Myeloid NGS panel, Myeloid DNA panel, Oncomine myeloid panel, Oncomine comprehensive panel, Myeloid DNA panel